Oncotarget

Reviews:

EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer

Xueli Nan, Chao Xie, Xueyan Yu and Jie Liu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:75712-75726. https://doi.org/10.18632/oncotarget.20095

Metrics: PDF 1542 views  |   HTML 3992 views  |   ?  


Abstract

Xueli Nan1,2, Chao Xie2, Xueyan Yu3 and Jie Liu2,4

1School of Medicine and Life Sciences, University of Ji’nan-Shandong Academy of Medical Sciences, Shandong, China

2Department of Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong, China

3Department of Oncology, Shandong Provincial Chest Hospital, Shandong, China

4Shandong Academy of Medical Sciences, Shandong, China

Correspondence to:

Jie Liu, email: lj1260814@126.com

Keywords: EGFR TKI, first-line treatment, non-small-cell-lung cancer, EGFR mutations, combined therapy

Received: February 21, 2017     Accepted: July 26, 2017     Published: August 09, 2017

ABSTRACT

After the discovery of activating mutations in EGFR, EGFR tyrosine kinase inhibitors (TKIs) have been introduced into the first-line treatment of non-small-cell lung cancer (NSCLC). A series of studies have shown that EGFR TKI monotherapy as first-line treatment can benefit NSCLC patients harbouring EGFR mutations. Besides, combination strategies based on EGFR TKIs in the first line treatment have also been proved to delay the occurrence of resistance. In this review, we summarize the scientific literature and evidence of EGFR TKIs as first-line therapy from the first-generation EGFR TKIs to conceptually proposed fourth-generation EGFR TKI, and also recommend the application of monotherapy and combination therapies of the EGFR-based targeted therapy with other agents such as chemotherapy, anti-angiogenic drugs and immunecheckpoint inhibitors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20095